Program
imeroprubart
Also written as “IMVT-1402” and “Imeroprubart”.
Its studies are mostly in Graves Disease · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Myasthenia Gravis · Lupus Erythematosus, Cutaneous · Arthritis, Rheumatoid, led by Immunovant Sciences.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Immunovant Sciences | 88 open or running | phase 3since Jun 18, 2025 | Dec 9, 2024 | May 2027phase 2 · NCT07018323 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 9, 2024First studies: 2 phase 2 studiesFirst studyNCT06727604, NCT06754462
- May 8, 20253 phase 2 studiesNCT06980805, NCT06979531, NCT07018323
- Jun 11, 2025Phase 2 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT07032662 · 162 planned · United States, Argentina, Australia and more
- Jun 18, 2025Phase 3 study in Myasthenia GravisNCT07039916 · 231 planned · United States, Argentina, Czechia and more
- Dec 10, 2025Phase 2 study in Graves DiseaseNCT07286006 · 372 planned · United States, Australia, Bulgaria and more
Ahead
- May 2027Primary completion: phase 2 study in Graves DiseaseNCT07018323
- Sep 2027Primary completion: phase 2 study in Arthritis, RheumatoidNCT06754462
- Dec 2027Primary completion: phase 3 study in Myasthenia GravisNCT07039916
- Jun 2028Primary completion: phase 2 study in Graves DiseaseNCT06727604
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07286006Graves Disease · United States, Australia, Bulgaria and more | 2 | By invitation | Mar 2030 | 372 |
| NCT07039916Myasthenia Gravis · United States, Argentina, Czechia and more | 3 | Recruiting | Dec 2027 | 231 |
| NCT07032662Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Argentina, Australia and more | 2 | Recruiting | Aug 2028 | 162 |
| NCT07018323Graves Disease · United States, Australia, Brazil and more | 2 | Recruiting | May 2027 | 210 |
| NCT06979531Primary Sjögren's Syndrome · United States, Argentina, Canada and more | 2 | Active, not recruiting | Jul 2028 | 180 |
| NCT06980805Lupus Erythematosus, Cutaneous · United States, Argentina, Bulgaria and more | 2 | Active, not recruiting | Oct 2026 | 56 |
| NCT06754462Arthritis, Rheumatoid · United States, Argentina, Bulgaria and more | 2 | Active, not recruiting | Sep 2027 | 120 |
| NCT06727604Graves Disease · United States, Belgium, Georgia and more | 2 | Recruiting | Jun 2028 | 240 |
How it is read
Names in the registry
- “IMVT-1402”, 11 entries
- “Imeroprubart”, 1 entry
Conditions, from the studies’ own filings
- Graves Disease, 3 studies
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, 1 study
- Myasthenia Gravis, 1 study
- Lupus Erythematosus, Cutaneous, 1 study
- Arthritis, Rheumatoid, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.